CathVision announced securing €13 million from Vaekstfonden et all
CathVision, a Copenhagen, Denmark-based medtech company developing a low-noise electrophysiology (EP ) recording system to help guide cardiac ablation therapy, announced the completion of a €13 million ($14M) capital investment round.
The money was provided by new and existing investors, including Vaekstfonden.
The proceeds allow the company to begin multi-center clinical studies and complete its FDA approval process for the CathVision Cube system and associated software algorithms.
CathVision, founded in 2013 and led by CEO Mads Emil Matthiesen, is developing and selling medical devices to treat cardiac arrhythmias. The solutions are centered on an innovative electrophysiology (EP) system to provide exceptional EP signals for identification and characterization of arrhythmias.